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Opinion statement
Cerebral small vessel disease (SVD) is characterised by damage to deep grey and white matter
structures of the brain and is responsible for a diverse range of clinical problems that include
stroke and dementia. In this review, we describe advances in neuroimaging published since
January 2015, mainly with magnetic resonance imaging (MRI), that, in general, are
improving quantification, observation and investigation of SVD focussing on three areas:
quantifying the total SVD burden, imaging brain microstructural integrity and imaging
vascular malfunction. Methods to capture ‘whole brain SVD burden’ across the spectrum of
SVD imaging changes will be useful for patient stratification in clinical trials, an approach
that we are already testing. More sophisticated imaging measures of SVD microstructural
damage are allowing the disease to be studied at earlier stages, will help identify specific
factors that are important in development of overt SVD imaging features and in understand-
ing why specific clinical consequences may occur. Imaging vascular function will help
establish the precise blood vessel and blood flow alterations at early disease stages and,
together with microstructural integrity measures, may provide important surrogate end-
points in clinical trials testing new interventions. Better knowledge of SVD pathophysiology
will help identify new treatment targets, improve patient stratification and may in future
increase efficiency of clinical trials through smaller sample sizes or shorter follow-up periods.
However, most of these methods are not yet sufficiently mature to use with confidence in
clinical trials, although rapid advances in the field suggest that reliable quantification of
SVD lesion burden, tissue microstructural integrity and vascular dysfunction are imminent.
Introduction
Cerebral small vessel disease (SVD) is a condition
resulting from damage to the cerebral microcircula-
tion and predominantly affects the blood supply and
tissue of the deep white and grey matter areas of the
brain [1].
Radiologically, it is characterised by recent small
subcortical infarcts that can present with stroke and
other lesions that are usually clinically ‘silent’ until
advanced such as white matter hyperintensities
(WMH) in the periventricular and deep white and
grey matter, enlarged perivascular spaces (PVS),
lacunes, microbleeds and cerebral atrophy [2]. These
features are present in up to 10% of patients in their
seventh decade rising to above 85% of those in their
ninth decade [3].
Clinical consequences of SVD are diverse. They
include lacunar ischaemic stroke (around a fifth of
all strokes), vascular and mixed dementias (SVD
contributes to 45% of all dementias), intracerebral
haemorrhages particularly in older people, gait
and balance dysfunction and dysfunction of the
bladder [1].
SVD is seen routinely on CT and MR imaging of
the brain. However, structural MRI including FLAIR,
T2-weighted, T1-weighted and gradient echo/T2*/
susceptibility-weighted sequences (and diffusion im-
aging for acute lesions) are best able to characterise
the full spectrum of features [2]. Increasingly, there
is a desire to investigate beyond basic structural
imaging in SVD as these changes may not fully
explain the variance in SVD [4] and tissue changes
are detectable prior to development of overt disease
on structural imaging. This stems from a revised
understanding of the potential pathophysiological
processes and a need to detect the earliest features
of SVD [1].
SVD is now understood to be distinct from large
vessel atherosclerotic vascular disease [1]. Both share
common risk factors such as age, hypertension, hy-
percholesterolaemia, diabetes and smoking [5].
However, large artery atheroma and ischaemic heart
disease correlate poorly with SVD burden once a
shared co-association with vascular risk factors is
accounted for [6]. Instead sporadic SVD increasingly
appears to be an intrinsic disorder of the endotheli-
um that leads to lipohyalinosis, vessel wall thicken-
ing of small cerebral arterioles, fibrinoid necrosis
and perivascular tissue injury [1]. There is also evi-
dence of primary abnormalities of the matrix pro-
teins and direct effects on myelination through im-
paired maturation of oligodendrocyte precursor cells,
rather than just direct damage to myelin. Each po-
tential abnormality offers possible opportunities for
new interventions, hence the importance of under-
standing SVD pathophysiology in patients. Tech-
niques are now developing to image endothelial
and blood vessel function, in vivo, in humans,
supporting the hypothesis that SVD is an endothelial
disease and thus likely to require different treatments
than thrombus and plaque-targeted traditional vascular
therapies [7].
Imaging endothelial function whilst measuring the
integrity of cerebral microstructures will increase patho-
physiological understanding of SVD. The recent explo-
sion in knowledge of SVD genetics [8] provides further
insights into disease triggers and accelerators. Associat-
ing clinical consequences with specific stages, radiolog-
ical features and microstructural disruption will allow
targeting of therapies to the most important steps in
SVD development. Of particular importance, advanced
imaging methods, if valid, reliable, reproducible and
relevant, can provide intermediary outcome markers of
early efficacy of new interventions in patients, helping to
narrow the field of potential therapies ahead of the large
clinical trials that will be required to show clinical ben-
efit by preventing stroke, functional dependence and
cognitive decline [9, 10].
In this article, we will summarise recent advances in
imaging SVD in the past 2 years. These have mainly
occurred in three key areas: (1) quantifying SVD burden,
(2) imaging microstructural integrity and (3) assessing
vascular malfunction. We have not included
microinfarcts, since there is a very recent update on them
in submission.
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Methods for this review
We searched EMBASE, MEDLINE and PUBMED for relevant systematic reviews
and primary articles between 1 January 2015 andMarch 2017. A separate search
was performed for each section and titles were screened by GB or MVH (see
supplementary information). Additionally, we hand-searched the Journal of
Cerebral Blood Flow and Metabolism over the same period, checked references in
opinion reviews and utilised the authors personal libraries of relevant articles in
neuroimaging and SVD.
We used recent systematic reviews where available as these are generally the
best summaries of the available evidence, updated with recent publications. We
assessed publications for study size, patient characteristics, imaging methods
and feature sought, evidence of validation, of adjustment for co-related vari-
ables in pathophysiological analyses and extracted information on the main
results. We did not use a quality assessment tool as this work was not a formal
systematic review and the literature was very diverse.
Quantification of SVD features
In recent years, efforts have been made to quantitatively assess specific SVD
markers on one hand and to devise metrics that allow the quantification of the
total burden of SVD on the other. We identified 48 articles since the start of
2015 that have attempted to computationally assess either WMH, ischaemic
stroke lesions, PVS, cerebralmicrobleeds or regions of interest reportedly related
to vascular dementia and SVD in general (Fig. 1 and Supplementary Table S1A).
In the same period, we identified nine articles that used a composite score
reflective of the total SVD burden (Table 1).
Classical machine learning-based classification algorithms like support vec-
tormachines (SVMs) and random forest lead the list of computationalmethods
Fig. 1. Graphical representation of the proportions of papers published since January 2015 until March 2017 on computational
methods to assess small vessel disease imaging markers and sample size involved. Legend: PVS perivascular spaces, WMH white
matter hyperintensities, BMB brain microbleeds, ROIs regions of interest.
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Table 1. Original papers published since 1 January 2015 on composite SVD scores
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applied to the assessment of SVD markers (16/48 studies in this period). They
have shown promise formaking high dimensional neuroimaging data clinically
useful, but identifying imaging-based patterns that contribute significantly to
classifier decisions remains an open problem. This is an issue of critical im-
portance in imaging studies seeking to determine which anatomical, textural or
physiological imaging features contribute to the classifier’s decision, thereby
allowing users to evaluate critically the findings of such machine learning
methods and to understand disease mechanisms. The majority of published
work addresses the question of statistical inference for support vector classifi-
cation using permutation tests based on SVMweight vectors. Such permutation
testing ignores the SVM margin, which is critical in SVM theory. A study
proposes a metric attempting to account for this margin [21], but given the
complexity of the global feature space in which coexist several manifolds, the
approach of separating ‘classes’ using a hyperplane does not always have the
best outcome. Deep learning approaches like convolutional neural networks
offer a solution to this problem. And, indeed, several studies have applied them
to assess SVD markers with promising results [22–26]. But still, conventional
thresholding and clustering approaches are being redefined in novel ways to
address the challenging issue of coping with the wide variation of abnormalities
present in the brain images of individuals with SVD. However, the application of
these recently developed methods to clinical research is still premature. Some of
themhave been developed using only a few representative datasets. Collaborative
efforts that allow them to be evaluated in large multicentre datasets and in
samples representative of the whole SVD spectrum are needed.
From the attempts to devise a composite SVD score representative of the
individual’s SVD burden, a major effort has beenmade by Staals and colleagues
[27•], based on visually rated individual SVD features and combines them into
the ‘total SVD burden’ on a scale of 0–4 [27•]. Initial efforts were further tested
and refined in larger datasets of patients with stroke and healthy older indi-
viduals, testing inclusion of additional features and different weighting of
individual feature scores, with the Edinburgh group [11, 17, 18]. In the current
version of the score, a point is attributed for each of the following: moderate to
severe WMH, presence of moderate to severe PVS in the basal ganglia, presence
of lacunes and presence of microbleeds.
This SVD score has been reported by multiple research groups to be associ-
ated to cognitive function. Staals et al. found in 680 community-dwelling
healthy elderly subjects of the Lothian Birth Cohort 1936 (LBC1936) that a
higher SVD score was associated with lower cognitive ability in older age and
performed well against an ‘SVD burden’ constructed using latent variable
modelling [11]. Uiterwijk et al. found an association of the SVD score with
cognitive decline over 4 years and specifically in the domains of executive
function and processing speed, with higher scores at baseline in patients
with hypertension [13]. Other studies have found the total SVD score was
also associated with gait and balance impairment in healthy older sub-
jects [18] and patients with vascular risk factors [15]. Using a different
composite score that looked at a broader range of cerebrovascular disease
burden incorporating both small and large vessel contributions, Xu et al.
also showed an association of their composite CeVD score with reduced
global cognitive function and particularly impairment of executive function,
language and visuoconstruction [14].
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Total SVD burden measures have also been associated with emerging SVD
risk factors. These include early life factors such as age 11 IQ, childhood
deprivation, education and class of occupation in the LBC1936 [17]. Pulse wave
velocity (PWV, a marker of arterial stiffness) which has previously been re-
peatedly shown to correlate with WMH has shown similar associations with a
composite SVD score [16]. One study has also linked aortic plaque to total SVD
severity [19]. Composite SVD scores have been used in investigations of other
medical conditions that may influence brain health, e.g. mild parkinsonian
signs [15] and in systemic lupus erythematosus [20]. One study also looked to
see if total SVD score could predict early neurological deterioration after stroke
but found no association [12].
A recent systematic review has highlighted the reproducibility and variability
in measuring SVD imaging features computationally and the factors that affect
these [28••]. The most studied features were brain atrophy (19 articles), WMH
(five articles) and microbleeds (four studies) with no studies addressing re-
producibility of PVS or lacunes. Whilst good within-centre reproducibility was
seen for brain atrophy and WMH, this was in small studies and between-centre
variability was much higher. Field strength, sequence type, scanner manufac-
turer, head coil, patient positioning and impact of scanner upgrades could all
affect reproducibility and variability [28••]. Larger studies of between-centre
reproducibility are required and study protocols and analysis should account
for these factors.
Measuring structural integrity
White matter structural and functional integrity can now be investigated in
greater detail with diffusor tensor imaging (DTI) techniques. Themost common
derived measures are fractional anisotropy (FA) and mean diffusivity (MD). FA
decreases and MD increases as white matter is damaged and diffusion is not
restricted to a single direction along the paths’ of axons. These provide a
quantitative measure of integrity in a given tract or region. Emerging techniques
are allowing these metrics to be converted into maps of connectivity or
‘connectome’. We identified 26 articles (n = 17,188) investigating SVD and
white matter integrity measured with DTI (Table S2).
A recent systematic review found DTI had been used to investigate white
matter integrity and SVD risk factors in one study of 499 patients (published in
four journal articles); cognition in SVD in 19 articles (n = 3620 patients,
although the number falls to 1402 patients when multiple articles on the same
cohorts are accounted for); depression in SVD in four studies (n = 733 patients);
motor effects of SVD in eight studies (n = 592 patients); and cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) in six studies (n = 307 patients). In general, the review found that FA
was decreased and MD increased in WMH and normal appearing white matter
(NAWM). NAWMwasmore abnormal close toWMH. Evidence that risk factors
were associated with microstructural damage in SVD was relatively sparse and
came from a single cohort (n = 499) but suggested that hypertension, smoking
and physical inactivity increased microstructural damage in NAWM although
some of these associations disappeared after correction for other SVD features.
Cognition remained associated with white matter integrity after taking into
account other imaging markers of SVD. Longitudinal associations between DTI
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metrics and declining cognition are less well established however. Whilst de-
pression has been linked with microstructural integrity, this relationship dis-
appeared when other SVD imaging markers or disability were controlled for.
Motor symptoms of SVD have been more consistently linked to NAWM integ-
rity, specifically disturbances of frontal microstructure, although this was based
on studies covering only five cohorts (n = 681). Overall, this review concluded
that DTI indices were associated with clinical features of SVD and that many of
these relationships remained apparent after correcting for other imaging
markers of SVD [29].
A further recent systematic review assessed the relationship of diabetes to
SVD [30]. Five of the 49 studies (n = 590) included in the review used DTI
measures and all had shown that FA was decreased and MD increased in
patients with diabetes [30].
Other studies published since these reviews found similar results but
emphasised that factors such as demographic variables and other SVD
imaging features must be accounted for when utilising DTI metrics to
avoid confounding [31–43].
The prognostic significance of decreased white matter integrity was not
assessed in these systematic reviews but some data have been published re-
cently. In 4259 subjects from the Rotterdam Study cohort, who were stroke-free
at inception, with over 18,476 person years of follow-up, impaired global white
matter integrity on DTI was associated with increased stroke risk: FA, hazard
ratio for strokewas 0.75 (0.57–0.98) per standard deviation increase in FA;MD,
HR 1.50 (1.08–2.09) per standard deviation increase in MD. The effect was
independent of age, sex, cardiovascular risk factors, WMH volume and lacunes
[44]. Each standard deviation decrease in FA and each SD increase in MD were
also associated with an increase in all causemortality (HR 1.37 (1.20–1.57) and
1.49 (1.28–1.75), respectively) over 5.4 years of follow-up, controlled for
demographic variables, vascular risk factors and other SVD imaging markers.
Further analysis indicated that the increased risk of death with falling FA was
specifically for cardiovascular not non-cardiovascular death [45].
Methods to increase the sensitivity of DTI measures to early white matter
injury are now being developed, for example the metric of ‘peak width of
skeletonizedmean diffusivity’ (PSMD) [46]. Thismethod skeletonises the white
matter tracts reduced the contamination from CSF containing structures and
increased sensitivity to the whole brain burden of SVD. PSMD was associated
with slower processing speed in patients with CADASIL and in patients with
sporadic SVD (but not in healthy controls or in patients with Alzheimer’s
Disease) and suggested that PSMD was more sensitive to progression of brain
injury from SVD than the individual features of WMH volume, lacune volume
or brain volume. Estimated sample sizes for a clinical trial with 18-month
follow-up suggested that PSMD had the smallest required sample size com-
pared to whole brain MD peak height, normalised WMH volume, brain pa-
renchymal fraction, processing speed score or normalised lacune volume [46].
Other studies have assessed the use of DTI measures in clinical trials. In SCANS
(patients with symptomatic lacunar infarcts and confluent WMH), changes in
MD, brain volume, WMH volume and lacunes were detectable over 3 years of
follow-up but not in cognitive scores: the lowest estimated sample size was
from WMH volume, followed by MD in NAWM [9]. This requires further
testing in other cohorts, since an analysis of 1-year follow-up in about 200
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patients with minor stroke and WMH in the Mild Stroke Study 2 suggested that
failure to account for WMH reduction as well as increase resulted in huge
sample sizes [47].
Connectivity imaging
The emerging field of connectomics allows DTI metrics to analyse the strength
and complexity of white matter connections between different brain regions
and the efficiency of these networks. For example, nodal efficiency is ameasure of
the path length between a node and all the other nodes in a network. Shorter
path lengths are more efficient. A decrease in nodal efficiency means commu-
nications are being routed by a longer path.
In a cohort of 232 patients with cognitive impairment of mixed aetiology,
WMH volume and lacunes were associated with decreased nodal efficiency in
frontal, lateral temporal, lateral parietal and occipital regions. Using path
analysis, frontal nodal efficiency appeared to mediate the effects of SVD on
frontal atrophy and frontal executive dysfunction. Temporal and parietal nodal
efficiency appeared to mediate the effects of SVD on temporal and parietal
atrophy and memory dysfunction [32].
In 38 patients without dementia but with probable CAA (based on Pitts-
burgh B PET imaging), including 17 participants with intracerebral haemor-
rhage, lower global network efficiency was related to higher cortical amyloid
load, WMH volume, atrophy and a trend towards significance for cerebral
microbleeds. Lower network efficiency was also related to worse performance
on processing speed and executive function tests and gait velocity but not
memory. The association of network efficiency with cognition persisted after
controlling for the SVD, but it was not stated how it compared to a simple FA
value [48]. A similar association with cognition was found in 27 patients with a
lacune on neuroimaging where global and local network efficiencies were
reduced compared to control and memory, attention, executive function and
verbal fluency were all associated with nodal efficiency [49].
Connectivity can also be investigated using resting state BOLD MRI tech-
niques to identify networks. In 19 patients with symptomatic subcortical stroke
producing motor deficits, functional connectivity assessed with resting state
BOLD MRI, between the M1 region and motor cortex in the contralateral
hemisphere, was reduced post-stroke. Structural connectivity in the corpus
callosummeasured using fibre tracking was also reduced compared to controls
[50].
Although promising as sensitivemarkers of early SVD-related brain damage,
considerably more work in different populations and particularly in longitu-
dinal studies is required to establish if structural or functional connectivity can
provide accessible, reliable, reproducible or relevant measures of microstruc-
tural damage or could be utilised as early efficacy markers in clinical trials.
Imaging microvascular malfunction
Several non-invasive techniques are available to investigate cerebral
haemodynamics in vivo. At the simplest, these estimate cerebral blood flow but
can be expanded tomeasure pulsatility throughout the cardiac cycle, blood flow
reactivity, blood-brain barrier leakage and metrics related to oxygen utilisation.
We identified 22 articles relevant to SVD using these techniques (Table S3).
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Cerebral blood flow and arterial stiffness
A recent systematic review and meta-analysis summarised current literature to
the end of 2015 on cerebral blood flow (CBF) and the most commonly studied
SVD feature, WMH. Four studies assessed CBF and WMH longitudinally whilst
34 were cross-sectional, 24 of which were suitable for meta-analysis. In cross-
sectional analysis, CBF (mostlymeasured in cortex or whole brain) was lower in
subjects with more WMH [51••], but this relationship was attenuated when
subjects with dementia and non-age-matched studies were excluded [51••].
Few studies measured CBF in either NAWM or in WMH. The four longitudinal
studies gave conflicting evidence: the largest (n = 575 patients [52]) found that
high WMH burden predicted falling CBF at follow-up but low CBF did not
predict increasingWMH in the long term; in the next largest (n = 390), low CBF
predicted progression of periventricular WMH only [53]); in 74 subjects, CBF
increased in some regions with WMH progression [54]; and the smallest study
(n = 40) found low CBF in regions where WMH developed at follow-up [55].
Peripheral arterial stiffness and its relationship to SVD imaging features
(including WMH, microbleeds, lacunes) and cognition were addressed in a
systematic review that included 23 studies (n = 15,666 participants) [56]. Eleven
of 15 studies of PWV or carotid stiffness and 6/12 studies of pulse pressure
showed an association between increasing arterial stiffness and SVD features. A
pooled analysis was possible for studies using PWVmeasures, showing that a one
standard deviation increase in PWV was associated with an increase in SVD
features (ORs between 1.29 and 1.32, p G 0.001) [56]. Sensitivity analysis showed
little effect of excluding studies considered to be at high risk of bias. There were 41
papers (n = 57,671 subjects) on the association between PWV and cognition but
between study heterogeneity precluded any pooled analysis. In terms of indi-
vidual studies of PWV, 6/11 cross-sectional studies found an association global
cognitive impairment, 5/22 cross-sectional studies found an association with
individual cognitive domains and 3/4 longitudinal studies found an association
with global cognitive decline. Pulse pressure was associated with global cognitive
impairment in 3/13 longitudinal and 4/13 cross-sectional studies [56].
Table S3 lists studies published since January 2015, most of which were
small (median n = 106) and found similar associations between PWV or pulse
pressure and SVD lesions or cognition [57–61]. The most relevant recent data
come from the Discontinuation of ANti-hypertensive Treatment in the Elderly
(DANTE) study [62]. DANTE provided a cross-sectional analysis of CBF and
blood pressure in 203 stroke-free, community-dwelling participants with some
cognitive impairment (MMSE 21–27) and a longitudinal sub-analysis of 102/
203 participants randomised to discontinue versus continue anti-hypertensive
treatment. Cross-sectionally, there was no association between CBF and any of
systolic BP, diastolic BP, pulse pressure, mean arterial pressure or change on
standing of systolic or diastolic BP in an age- and sex-adjusted analysis, re-
gardless of WMH volume, presence of microbleeds or lacunes. Longitudinally,
the change in CBF over 4 months follow-up did not differ between those who
continued versus those who stopped anti-hypertensive therapy. These findings
from an interventional trial suggest that blood pressure is not a major influence
on CBF in older cognitively impaired subjects despite hypertension being one
of the strongest risk factors for SVD. This further highlights that reduced CBF
does not fully explain the development of SVD.
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A modest literature on intracranial vascular stiffness, mostly assessed using
transcranial Doppler (TCD), was summarised in a systematic review prior to
2015 [63]. Intracranial arterial flow velocity, assessed with TCD, is well
established to increase with age and WMH score independent of vascular risk
factors (age = 0.2 cm s−1 fall in velocity/year increase in age, p = 0.045; WMH
score, 3.75 cm s−1 fall in flow velocity/point Fazekas score increase, p = 0.004)
[64] and others have suggested that middle cerebral artery velocities assessed
with TCD could be used as a proxymeasure ofWMHburden [65]. However, the
relationship between flow velocity, CBF and pulsatility is complex. Some
researchers are now starting to investigate other flow parameters including
transit times and intracranial blood flow pulsatility. Transit times may reflect
compensatory increase in blood volume to counter reduced CBF or slower
transit due to longer vascular pathways for example due to shunting or other-
wise dysregulated flow [66]. Consistent with the latter theory, Arba and col-
leagues examined CBF, cerebral blood volume (CBV) and MTT in 120 patients
with acute stroke and found a near-linear increase in transit timewith increasing
WMH score [67], with much less effect on CBF or CBV. The falling flow velocity
may reflect increasing pulsatility, since the two tend to go hand in hand;
however, whilst intracranial measures of arterial stiffness are clearly related to
increasing age [68, 69], evidence of a direct relationship to SVD features is
currently weak [69, 70]. Notwithstanding the clear associations between sys-
temic arterial stiffness and cerebral SVD imaging features, an association with
intracranial stiffness should not be assumed and studies with better defined
SVD populations corrected for demographics and risk factors are required. In
the future, it is now possible to image pulsatility and blood flow velocities in
individual perforating arterioles down to 80 μm in diameter with 7 TMRI [71•].
Cerebrovascular reactivity
Dynamic function of the cerebral blood vessels at voxel level is now an acces-
sible technique. Cerebrovascular reactivity (CVR) measures the brain’s vascular
response to a vasoactive stimulus, such as inhaling carbon dioxide (CO2).
Combining hypercapnia withMRI allows tissue level quantification of CVR and
is therefore an advance on cerebral vasomotor response assessed with TCD of
the middle cerebral artery [63].
We systematically reviewed all studies of CVR in SVD between 1990 and
2015 and found five studies (n = 155), but these provided insufficient data to
determine the relationship between CVR and SVD [72]. Two of five relevant
studies (n = 17) showed that decreased CVR was associated with increased
WMH but included only 11% of the patients in the five studies. The other three
larger studies showed no association. CVR was also shown to decrease with age
in three studies and female gender and diastolic BP in one study [72]. Clearly
more data are needed.
Since this review, CVR has been assessed in two published studies. CVR was
lower in areas of NAWM that became WMH in a longitudinal study (n = 45)
[73]. Areas of negative CVR, i.e. reduced flow during CO2 inhalation suggesting
areas are at risk of ischaemia due to vascular steal, have also been associated
with lower CBF and microstructural damage in a study of 75 patients [74].
Whilst intriguing, further studies controlling for age, vascular risk factors and
baseline WMH volume are needed.
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We assessed CO2-challenge MRI CVR (and in parallel assessed intracranial
vascular pulsatility) in an observational cross-sectional study (n = 60) [75] in
which we found associations between falling CVR and increasingWMHburden
and increased PVS visibility (and increased pulsatility and WMH burden). We
and others are now determining if the CO2 MRI CVR method can be used in
multicentre observational studies (INVESTIGATE@SVDs ISRCTN10514229)
and in randomised clinical trials testing potential SVD treatments as an inter-
mediary marker of efficacy (LACI-1 ISRCTN 12580546; TREAT@SVDs
Clinicaltrials.gov registration in process). Determining if the CVR method is
sensitive and reliable enough to use in multicentre studies would make a
potentially very powerful technique available for large-scale trials and
population studies.
Blood-Brain barrier (BBB) leakage
The blood-brain barrier (BBB) normally regulates material entering and
leaving the brain to maintain homeostasis of the brain cell environment.
However, it becomes subtly more leaky with advancing age [76], very
obviously more leaky following acute ischaemic, traumatic or oncological
injury, and it is subtly more leaky than normal in SVD. Measures of BBB
permeability in vivo are available to assess cerebral vascular endothelial
integrity such as dynamic contrast enhanced MRI and CT perfusion
techniques although caution is required since methods to assess subtle
BBB leak are still evolving.
Until February 2014, 70 studies had been performed using DCE-MRI to
assess BBB permeability that covered 417 individual animals and 1564
humans. Of conditions potentially relevant to SVD, BBB leakage was assessed in
482 stroke patients, 30 Alzheimer’s disease (AD) patients, 22 mild cognitive
impairment (MCI) patients and 20 diabetic patients. Differences in diseased
subjects compared to controls were found in acute ischaemic stroke, vascular
cognitive impairment, mild cognitive impairment, SVD and AD. Two studies
were identified that reported impaired BBB permeability in lacunar versus
cortical stroke.
A recent systematic review on BBB leakage in humans during ageing, in SVD
or dementia, identified six studies including 203 patients [77]. This identified that
BBB was more permeable in white matter and deep grey matter in those with
diabetes-associated MCI, more permeable in lacunar stroke patients than
atherothromboembolic stroke in white matter and CSF and more permeable in
white matter in patients with WMH and both AD and vascular dementia and in
the hippocampus in patients with MCI.
We assessed BBB leakage in 204 patients with minor stroke, doubling the
sample available in the literature. As well as differences inWM integrity between
WMH and NAWM, permeability assessed by DCE-MRI slope enhancement was
increased in WMH compared to NAWM [43, 77, 78], and in NAWM close to
versus remote from WMH, when adjusted for age, WMH burden, vascular risk
factors and important methodological variables such as baseline T1 value and
time after contrast injection. Additionally, leakage increased with age, hyper-
tension and WMH severity and predicted declining cognition at 1-year follow-
up [77].
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Other small studies in the last few years have found similar results [79–81],
although many did not adjust for important demographic variables and risk
factors [79, 80] (Table S3).
Despite the growing interest in assessing low-level BBB leakage using DCE-
MRI, it should be noted that this is a very difficult technique with imaging, since
the signal changes caused by slow leakage are small, take a long time to acquire
and are typically of comparable magnitude to the level of noise, artefact and
instrumental or biological signal drift all of which have to be accounted for.
Most prior studies have not done this. There is also no agreed minimum
standard acquisition protocol, signal modelling method and parameters to be
reported. Several groups have reported on the pitfalls and limitations of the
technique, and the results of which should be interpreted with caution [78, 82–
84]. The standardisation of the BBB leakage method for studies in SVD is now
being assessed in an international Working Group (HARNESS) funded by the
multinational Joint Programme for Neurodegenerative Diseases (JPND).
Conclusion
SVD remains a condition of many unknowns. Known SVD vascular risk factors
do not fully explain the variance in SVD development. Clinical consequences
are diverse: some individuals are symptomatic at early stages, and others have
large radiological disease burdens and no apparent symptoms. SVD even
appears reversible in some individuals. There remains no effective, specific
treatment to halt radiological or clinical progression of SVD.
The realisation that SVD is distinct from both large vessel atherosclerotic
vascular disease and normal ageing has only been accepted relatively recently.
The increased availability of increasingly sophisticated neuroimaging that can
unpick differences in tissue structure and vascular function and relate these
closely to symptoms in people has been key to this. Further development of
advanced neuroimaging techniques holds the key to improving our knowledge
and treatment of SVD, but crucially, this must be accompanied by demon-
strating that the methods are reliable, repeatable, relevant, tolerable and acces-
sible to affected patients.
In this review, we have described how better quantification of the total brain
burden of SVDmay help stratify patients more effectively than using individual
features and improve the understanding of the causes and consequences of
SVD. Imaging microstructural integrity and vascular malfunction are allowing
us to identify much earlier disease stages and tissue at risk of progression to
more established, later stage SVD brain damage. The focus of studies in SVD
should not only be to limit progression of brain damage but to try to reverse it
before it becomes permanent. Whilst these tissue level metrics have the poten-
tial to help understand what structures are damaged, and in what way, in each
of the specific clinical consequences of SVD, most of these methods are not yet
mature enough for use in large clinical trials.
Finally, an improved understanding of the pathophysiology of SVD, and its
drivers at different disease stages, will identify new treatment targets. The use of
more sensitive advanced imaging metrics as surrogate outcomes then also has the
potential to facilitate clinical trials with smaller samples and shorter follow-up
periods to accelerate discovery of effective treatments as efficiently as possible.
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